Atezolizumab Plus Bevacizumab for <scp>TACE</scp> ‐Unsuitable Intermediate‐Stage <scp>HCC</scp> Beyond Up‐To‐7 Criteria: Final Analysis of <scp>REPLACEMENT</scp>
Kurume University (JP), Kyushu University (JP), Fujita Health University (JP), Chiba University (JP), Iwate Medical University (JP), Yokohama City University Medical Center (JP), Kyoto Prefectural University of Medicine (JP), Osaka International Cancer Institute (JP), Kanazawa University Hospital (JP), Hiroshima Prefectural Hospital (JP), National Cancer Center Hospital East (JP), Ehime Prefectural Central Hospital (JP), Musashino Red Cross Hospital (JP), Sendai Kousei Hospital (JP), Kobe University (JP), The University of Tokyo (JP), Yokohama City University (JP), Kindai University (JP), Kumamoto University (JP)